Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial

1. Perez, E.A.
2. Awada, A.
3. O'Shaughnessy, J.
4. Rugo, H.S.
5. Twelves, C.
6. Im, S.-A.
7. Gómez-Pardo, P.
8. Schwartzberg, L.S.
9. Diéras, V.
10. Yardley, D.A.
11. Potter, D.A.
12. Mailliez, A.
13. Moreno-Aspitia, A.
14. Ahn, J.-S.
15. Zhao, C.
16. Hoch, U.
17. Tagliaferri, M.
18. Hannah, A.L.
19. Cortes, J.